Webinars

Cell therapy professionals were invited to join a specialist webinar by industry experts from PCI Pharma Services and TrakCel on Wednesday, April 20, addressing the unique complexity of an autologous therapy supply chain.

Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, PCI associate director, clinical services, and Dr. Matthew Lakelin, TrakCel Vice President Scientific Affairs and Business Development.

Commenting on the emergence of cell therapy approaches, Rachel said: “Cell-based therapies are being used increasingly to treat many diseases for which no other adequate treatment options are currently available. These therapies contain modified human cells that can regenerate or augment a recipient’s dysfunctional cells, tissues or organs. Cells’ biological characteristics are typically altered ex vivo before administration of the final product to patients.”

Explaining the complexity of the cell therapy supply chain, Matthew said: “Every constituent of the supply chain must be seamlessly orchestrated for a cell therapy product to reach every patient. From collection of cells through production into a drug product and reverse logistics back to the patient, this process is very complex but a risk based approach can mitigate potential challenges.”

PCI and TrakCel’s free learning event concentrated on:

  • How product characteristics can influence the management of the cell therapy supply chain
  • What might influence the decision to have centralized or localized manufacturing strategies
  • The information required to successfully import and export cell therapy materials.

The webinar is available to view below:

Posted on Categories Webinars

Leave a Reply

Your email address will not be published. Required fields are marked *

1 + 12 =

Explore the PCI Process Phase by Phase

PRE-CLINICAL
PHASE I
PHASE II
PHASE III
COMMERCIAL

Swipe to explore the PCI Process

PRE CLINICAL

pre-clinical-icon
  • Formulation Development
  • Analytical development/characterisation

PHASE 1

PCI Phase 1
  • Formulation Development
  • Analytical Development
  • Drug in capsule/vial technology (Xcelodose)®
  • Phase I product manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase I packaging and labelling
  • Storage and distribution

PHASE 2

PCI Phase 2
  • Formulation Optimization
  • Dosage Form Process Validation
  • Analytical Testing and Stability Services
  • Phase II Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase II packaging and labelling
  • Storage and distribution

PHASE 3

PCI Phase 3
  • Comparator Sourcing
  • Scale Up Studies
  • Phase III Product Manufacture
  • Tablets/Capsules
  • Blinding via over-encapsulation
  • Phase III packaging and labelling
  • Analytical testing and stability services
  • Storage and distribution

COMMERCIAL

PCI Commercial Phase
  • Scale up for commercial supply
  • Commercial product manufacture
  • Commercial packaging and labelling
  • Validation services
  • Analytical testing and stability services
  • Product release to market
  • Storage and distribution

PCI Points...

You told us what aspects you value as "very important" when choosing a vendor...

Why choose us...

Our global reach and localized support ensures PCI as a strategic partner remains focussed on delivering speed-to-market and the commercial success of our customers

PCI is a global company that focusses on delivering speed-to-market and the commercial success of our customers

Why choose us...